Hansoh Pharmaceutical Group (HKG:3692) has obtained drug registration approval for Hengmeida (Ibrexafungerp tablets) from China's National Medical Products Administration, an April 25 Hong Kong bourse filing said.
The approval is for use of the drug to treat vulvovaginal candidiasis in adult and post menarche adolescent women.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.